Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market Report 2026

Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market Overview

• Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) market size has reached to $0.88 billion in 2025 • Expected to grow to $1.66 billion in 2030 at a compound annual growth rate (CAGR) of 13.5% • Growth Driver: Surge In Infectious Diseases Fueling The Growth Of The Market Due To Increasing Transmission Rates And Rising Tuberculosis Incidence • Market Trend: Regulatory Advancements In Tuberculosis Diagnostics Strengthen Global Access And Early Disease Detection • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market?

A point of care (POC) tuberculosis (TB) ultra-sensitive nucleic acid amplification test (NAAT) is a rapid molecular diagnostic assay developed to detect the genetic material of Mycobacterium tuberculosis at or near the patient care setting. It employs advanced amplification techniques to identify extremely low bacterial concentrations with high sensitivity and specificity, facilitating early and reliable diagnosis. A point-of-care tuberculosis ultra-sensitive nucleic acid amplification test designed to be compact and automated, the test delivers quick results, enabling prompt clinical decisions and effective disease management. The main technologies of point-of-care tuberculosis ultra-sensitive nucleic acid amplification test include polymerase chain reaction based nucleic acid amplification testing, isothermal amplification, and others. Polymerase chain reaction (PCR)-based nucleic acid amplification testing (NAAT) is a molecular technique that rapidly amplifies and detects specific DNA or RNA sequences to identify pathogens or genetic material with high sensitivity. The product types include instruments, reagents and consumables, and software and are performed using sample types such as sputum, blood, urine, and other sample types. The key end users include hospitals and clinics, diagnostic laboratories, research institutes, and other end users.

What Is The Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market Growth Forecast?

The point of care (POC) tuberculosis (TB) ultra-sensitive nucleic acid amplification test (NAAT) market size is expected to see rapid growth in the next few years. It will grow to $1.66 billion in 2030 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be attributed to demand for ultra-sensitive point-of-care testing, integration of ai with diagnostic assays, expansion of decentralized healthcare, investment in rapid nucleic acid amplification technologies, increasing funding for tuberculosis control programs. Major trends in the forecast period include rapid point-of-care testing, ultra-sensitive nucleic acid amplification, automated diagnostic platforms, compact & portable test devices, integration with electronic health records.

What Is The Driver Of The Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market?

The rising prevalence of infectious diseases is expected to propel the growth of the point of care (POC) tuberculosis (TB) ultra-sensitive nucleic acid amplification test (NAAT) market going forward. Infectious diseases are disorders caused by pathogenic microorganisms such as bacteria, viruses, parasites, or fungi that spread directly or indirectly between individuals. The rising prevalence of infectious diseases is driven by increasing global population density, which accelerates transmission risks and disease spread. Point-of-care tuberculosis ultra-sensitive nucleic acid amplification testing supports the rising prevalence of infectious diseases by enabling rapid, highly sensitive, and decentralized detection of infectious pathogens, which strengthens early diagnosis and disease control efforts. For instance, in March 2025, according to the UK Health Security Agency, a UK-based government health authority, tuberculosis cases in England increased by 13% in 2024, reaching 5,480 cases compared to 4,850 cases in 2023. Therefore, the rising prevalence of infectious diseases is driving the growth of the point of care (POC) tuberculosis (TB) ultra-sensitive nucleic acid amplification test (NAAT) industry.

Key Players In The Global Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market

Major companies operating in the point of care (POC) tuberculosis (TB) ultra-sensitive nucleic acid amplification test (NAAT) market are (POC) tuberculosis (TB) ultra-sensitive nucleic acid amplification test (NAAT) market are F. Hoffmann-La Roche AG, Abbott Laboratories, Danaher Corporation, QIAGEN N.V., SD BIOSENSOR Inc., Eiken Chemical Co. Ltd, Oxford Nanopore Technologies Ltd, Molbio Diagnostics Limited, Sansure Biotech Inc., CapitalBio Corporation, QuantuMDx Group Limited, Tata Medical Diagnostics Limited, Ustar Biotechnologies, Mylab Discovery Solutions Private Limited, GenoScreen SAS, Co-Diagnostics Inc., Longhorn Vaccines Diagnostics LLC, Akonni Biosystems Inc., Zeesan Biotech Co. Ltd, Redcliffe labs.

Global Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market Trends and Insights

Major companies operating in the point of care (POC) tuberculosis (TB) ultra-sensitive nucleic acid amplification test (NAAT) market are focusing on regulatory validation and international prequalification programs to enhance quality assurance, accelerate global adoption, and improve access to high-sensitivity diagnostic solutions. Prequalification refers to a regulatory assessment process that evaluates in vitro diagnostic products for compliance with international standards of quality, safety, and performance, enabling procurement by global health agencies and deployment in resource-limited settings. For instance, in December 2024, the World Health Organization, a Switzerland-based intergovernmental organization, announced the first prequalification of an Xpert MTB/RIF, an ultra-tuberculosis diagnostic test, under its regulatory assessment framework. This milestone supports the expansion of reliable and rapid TB detection tools, particularly across low- and middle-income countries. Leveraging advanced nucleic acid amplification technology, cartridge-based automated systems, and rapid result turnaround capabilities, the solution facilitates decentralized testing, improves early case detection, and strengthens drug-resistance identification. It is specifically engineered for deployment in primary healthcare facilities and remote regions with limited laboratory infrastructure, thereby enhancing surveillance capacity, reducing diagnostic delays, and supporting global tuberculosis control and antimicrobial resistance management initiatives.

What Are Latest Mergers And Acquisitions In The Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market?

In March 2023, the Global Fund to Fight AIDS, Tuberculosis, and Malaria, a Switzerland-based government agency; the United States Agency for International Development (USAID), a US-based government agency; and Stop TB, a Switzerland-based non-profit organization, announced a collaboration with Molbio Diagnostics Pvt. Ltd. to increase global access to rapid molecular diagnostic tests for tuberculosis. Through this collaboration, the organizations aim to scale up the availability of point-of-care, ultra-sensitive nucleic acid amplification tests (NAATs) for TB detection, particularly in high-burden and resource-limited settings, thereby strengthening early diagnosis and treatment initiation efforts worldwide. Molbio Diagnostics Pvt. Ltd. is an India-based manufacturer of portable, cartridge-based molecular platforms (such as Truenat) designed for rapid, near-patient TB detection using nucleic acid amplification technology.

What Defines the Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market?

The point of care (POC) tuberculosis (TB) ultra-sensitive nucleic acid amplification test (NAAT) market consists of revenues earned by entities by providing services such as regulatory compliance support services, distribution and logistics services, and after-sales support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The point-of-care tuberculosis ultra-sensitive nucleic acid amplification test market also includes sales of disposable pipette tips, microfluidic chips, control materials, and calibration kits. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data And Analysis Are Included In The Point Of Care (POC) Tuberculosis (TB) Ultra-Sensitive Nucleic Acid Amplification Test (NAAT) Market Report 2026?

The point of care (poc) tuberculosis (tb) ultra-sensitive nucleic acid amplification test (naat) market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the point of care (poc) tuberculosis (tb) ultra-sensitive nucleic acid amplification test (naat) industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.